MAGNOLIA, Texas--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric marketplace, today announced results for the first quarter ended March 31, 2010. Net sales were approximately $8,873,000 and $7,235,000 for the three months ended March 31, 2010 and 2009, respectively, an increase of approximately $1,638,000, or 23%. This increase is primarily due to sales of new products, including our BROVEX product line, PEDIATEX TD, and REZYST, as well as increases in unit prices and the expansion of Pernix’s sales force in additional territories offset by a decrease in the sales of ALDEX products and Z-Cof.
